The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis
Open accessAbstract
OBJECTIVES: Despite significant medical advances, infective endocarditis (IE) remains an infection associated with high morbidity and mortality. The objective was to assess the safety and efficacy of high-dose daptomycin, defined as ≥ 8 mg/kg/day, in patients with confirmed or suspected staphylococcal and/or enterococcal IE. METHODS: This was a multicentre, retrospective observational study (2005-11). Adult patients, not undergoing haemodialysis, with blood cultures positive for staphylococci or enterococci and a definitive or possible diagnosis of IE, who received daptomycin ≥ 8 mg/kg/day (based on total body weight) for ≥ 72 h were included. RESULTS: Seventy patients met the inclusion criteria and comprised 33 (47.1%) with right-sided IE (RIE), 35 (50%) with left-sided IE (LIE) and 2 with both RIE and LIE. Several patients had concomitant sites of infection, with bone/joint infection being most prevalent (12.9%). Sixty-five patients received daptomycin as salvage therapy. Pathogens were isolated from 64 patients, with methicillin-resistant Staphylococcus aureus as the most common organism (84.4%), followed by vancomycin-resistant Enterococcus faecium (7.8%). The median (IQR) daptomycin dose was 9.8 mg/kg/day (8.2-10.0 mg/kg/day), and was similar in RIE and LIE patients (9.8 and 9.3 mg/kg/day, respectively). A total of 24 (34.3%) received combination therapy. For those patients with pathogens isolated (n = 64), the organism was eradicated in 57 (89.1%) patients. Among 64 clinically evaluable patients, 55 (85.9%) achieved clinical success. No patients required discontinuation of high-dose daptomycin due to creatine phosphokinase elevations. CONCLUSIONS: Patients with both RIE and LIE had successful outcomes with high-dose daptomycin therapy. Additional clinical trials evaluating high daptomycin dosages in patients with IE are warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Self-citationProposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir034 · Cited by 1,599
Self-citationDaptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Self-citationStaphylococcus aureus Endocarditis: A Consequence of Medical Progress
Fowler, V. G., Miro, J. M., Hoen, B., Cabell, C. H., Abrutyn, E., Rubinstein, E., Corey, G. R., Spelman, D., Bradley, S. F., Barsic, B., et al. (2005) · JAMA · doi:10.1001/jama.293.24.3012 · Cited by 1,174
Self-citationEmergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat
Grundmann, H., Aires-de-Sousa, M., Boyce, J., & Tiemersma, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68853-3 · Cited by 1,101
Arbeit, R. D., Maki, D., Tally, F. P., Campanaro, E., Eisenstein, B. I., & Daptomycin 98-01 and 99-01 Investigators (2004) · Clinical Infectious Diseases · doi:10.1086/420818 · Cited by 689
Lodise, T. P., Graves, J., Evans, A., Graffunder, E., Helmecke, M., Lomaestro, B. M., & Stellrecht, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00113-08 · Cited by 553
Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir124 · Cited by 463
Self-citationHealth Care–Associated Native Valve Endocarditis: Importance of Non-nosocomial Acquisition
Benito, N., Miró, J. M., de Lazzari, E., Cabell, C. H., del Río, A., Altclas, J., Commerford, P., Delahaye, F., Dragulescu, S., Giamarellou, H., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00004 · Cited by 277
Cited by
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv319 · Cited by 4,997
Baddour, L. M., Wilson, W. R., Bayer, A. S., Fowler, V. G., Tleyjeh, I. M., Rybak, M. J., Barsic, B., Lockhart, P. B., Gewitz, M. H., Levison, M. E., et al. (2015) · Circulation · doi:10.1161/cir.0000000000000296 · Cited by 3,232
Self-citation2023 ESC Guidelines for the management of endocarditis
Delgado, V., Ajmone Marsan, N., de Waha, S., Bonaros, N., Brida, M., Burri, H., Caselli, S., Doenst, T., Ederhy, S., Erba, P. A., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad193 · Cited by 1,754
Hassoun, A., Linden, P. K., & Friedman, B. (2017) · Critical Care · doi:10.1186/s13054-017-1801-3 · Cited by 604
“Furthermore, some studies suggest prior vancomycin failure is correlated with the acquisition of heteroresistance and reduced success of daptomycin therapy [12, 15, 16].”
BackgroundHolland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Sandoe, J. A. T., Barlow, G., Chambers, J. B., Gammage, M., Guleri, A., Howard, P., Olson, E., Perry, J. D., Prendergast, B. D., Spry, M. J., et al. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku383 · Cited by 403
JCS 2017 Guideline on Prevention and Treatment of Infective Endocarditis
Nakatani, S., Ohara, T., Ashihara, K., Izumi, C., Iwanaga, S., Eishi, K., Okita, Y., Daimon, M., Kimura, T., Toyoda, K., et al. (2019) · Circulation Journal · doi:10.1253/circj.cj-19-0549 · Cited by 179
2015 ESC Guidelines for the management of infective endocarditis
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J.-P., Del Zotti, F., Dulgheru, R., El Khoury, G., Erba, P. A., Iung, B., et al. (2015) · Kardiologia Polska · doi:10.5603/kp.2015.0227 · Cited by 165
Smith, J. R., Barber, K. E., Raut, A., Aboutaleb, M., Sakoulas, G., & Rybak, M. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv007 · Cited by 148
Self-citationBritt, N. S., Potter, E. M., Patel, N., & Steed, M. E. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw815 · Cited by 113
“The definition of “high-dose” daptomycin varies in the literature, but is most commonly ≥ 8 mg/kg or ≥ 10 mg/kg [18-23].”
BackgroundInfluentialTherapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections
Cairns, K. A., Udy, A. A., Peel, T. N., Abbott, I. J., Dooley, M. J., & Peleg, A. Y. (2023) · Clinical Microbiology Reviews · doi:10.1128/cmr.00059-22 · Cited by 111
Combination Antibiotic Treatment of Serious Methicillin-Resistant Staphylococcus aureus Infections
van Hal, S. J., Tong, S. Y. C., & Davis, J. S. (2015) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0034-1396906 · Cited by 116
Potentials of nanotechnology in treatment of methicillin-resistant Staphylococcus aureus
Gao, Y., Chen, Y., Cao, Y., Mo, A., & Peng, Q. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.113056 · Cited by 107
Stefani, S., Campanile, F., Santagati, M., Mezzatesta, M. L., Cafiso, V., & Pacini, G. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.05.008 · Cited by 107
Galar, A., Weil, A. A., Dudzinski, D. M., Muñóz, P., & Siedner, M. J. (2019) · Clinical Microbiology Reviews · doi:10.1128/cmr.00041-18 · Cited by 102
Domenico, E. G. D., Rimoldi, S. G., Cavallo, I., D’Agosto, G., Trento, E., Cagnoni, G., Palazzin, A., Pagani, C., Romeri, F., Vecchi, E. D., et al. (2019) · BMC Microbiology · doi:10.1186/s12866-019-1596-2 · Cited by 96
Combatting resistant enterococcal infections: a pharmacotherapy review
Mercuro, N. J., Davis, S. L., Zervos, M., & Herc, E. S. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1479397 · Cited by 98
Self-citationTurnidge, J. D., Kahlmeter, G., Cantón, R., MacGowan, A. P., & Giske, C. G. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.04.027 · Cited by 92
Intermittent antibiotic treatment of bacterial biofilms favors the rapid evolution of resistance
Usui, M., Yoshii, Y., Thiriet-Rupert, S., Ghigo, J., & Beloin, C. (2023) · Communications Biology · doi:10.1038/s42003-023-04601-y · Cited by 87
When sepsis persists: a review of MRSA bacteraemia salvage therapy
Kullar, R., Sakoulas, G., Deresinski, S. C., & van Hal, S. J. (2015) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv368 · Cited by 75
Self-citationSmith, J. R., Barber, K. E., Raut, A., & Rybak, M. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00053-15 · Cited by 62
Self-citationEmpirical therapy in Methicillin-resistant Staphylococcus Aureus infections: An Up-To-Date approach
VanEperen, A. S., & Segreti, J. (2016) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2016.02.012 · Cited by 68
Self-citationWhat’s New in the Treatment of Enterococcal Endocarditis?
Nigo, M., Munita, J. M., Arias, C. A., & Murray, B. E. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0431-z · Cited by 59
Seaton, R. A., González-Ruiz, A., Cleveland, K. O., Couch, K. A., Pathan, R. B., & Hamed, K. A. (2016) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-016-0130-8 · Cited by 52
“%) patients, and serious AEs (SAEs) were reported in 1050 (9.1”
BackgroundResultInfluentialBloem, A., Bax, H. I., Yusuf, E., & Verkaik, N. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081743 · Cited by 49
Bacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus
Bergin, S. P., Holland, T. L., Fowler, V. G., & Tong, S. Y. C. (2015) · Current topics in microbiology and immunology · doi:10.1007/82_2015_5001 · Cited by 49
Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci
Munita, J. M., Murray, B. E., & Arias, C. A. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.08.002 · Cited by 45
Bacteremia due to Methicillin-Resistant Staphylococcus aureus
Holubar, M. K., Meng, L., & Deresinski, S. C. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2016.02.009 · Cited by 46
Snyder, A. D. H., Werth, B. J., Nonejuie, P., McRoberts, J. P., Pogliano, J., Sakoulas, G., Yim, J., Singh, N. B., & Rybak, M. J. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00687-16 · Cited by 41
Self-citationTimbrook, T. T., Caffrey, A. R., Luther, M. K., Lopes, V., & LaPlante, K. L. (2017) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2070 · Cited by 39
Wang, G., Yu, F., Lin, H. C., Murugesan, K., Huang, W., Hoss, A. G., Dhand, A., Lee, L. Y., Zhuge, J., Yin, C., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0209785 · Cited by 34
Towards a definition of daptomycin optimal dose: Lessons learned from experimental and clinical data
Senneville, É., Caillon, J., Calvet, B., & Jehl, F. (2015) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2015.11.005 · Cited by 39
Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis
Durante‐Mangoni, E., Andini, R., Parrella, A., Mattucci, I., Cavezza, G., Senese, A., Trojaniello, C., Caprioli, R., Diana, M. V., & Utili, R. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.022 · Cited by 35
“Also, the actual number of IE patients included in these studies was limited, ranging from 15 to 70 [14–19].”
BackgroundResultInfluentialDaptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients
D’Avolio, A., Pensi, D., Baietto, L., Pacini, G., Perri, G. D., & Rosa, F. G. D. (2016) · Drugs · doi:10.1007/s40265-016-0610-3 · Cited by 35
Cota, J. M., FakhriRavari, A., Rowan, M. P., Chung, K. K., Murray, C. K., & Akers, K. S. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.08.001 · Cited by 35
Critical Questions About Left-Sided Infective Endocarditis
Román, J. A. S., Vilacosta, I., López, J., & Sarriá, C. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.07.016 · Cited by 35
High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It
Smith, J. R., Claeys, K. C., Barber, K. E., & Rybak, M. J. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0429-6 · Cited by 31
“9 %) patients on daptomycin therapy experiencing treatment-related adverse effects [55].”
Self-citationOrtwine, J. K., & Bhavan, K. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1435128 · Cited by 33
“Neither is it immune to the pitfalls of bacterial evolution; nonsusceptible isolates have been noted [8,9], although there is no significant trend toward resistance [46].”
BackgroundTzoumas, A., Sagris, Μ., Xenos, D., Ntoumaziou, A., Kyriakoulis, I., Kakargias, F., Liaqat, W., Nagraj, S., Patel, R., Korosoglou, G., et al. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.023 · Cited by 43
Fan, T., Hu, X., Tang, S., Liu, X., Wang, Y., Deng, H., You, X., Jiang, J., Li, Y., & Song, D. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00094 · Cited by 27
Zheng, J., Sun, X., Lin, Z., Qi, G.-B., Tu, H.-P., Wu, Y., Jiang, S., Chen, Z., Deng, Q.-W., Qu, D., et al. (2019) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000945 · Cited by 26
Wang, C., Ye, C., Liao, L., Wang, Z., Hu, Y., Deng, C., & Liu, L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01377-20 · Cited by 26
“While DAP has been effective against MRSAB, unsusceptible 59 isolates and treatment failures have been noted(8,9).”
González-Ruiz, A., Gargalianos-Kakolyris, P., Timerman, A., Sarma, J., Ramallo, V. J. G., Bouylout, K., Trostmann, U., Pathan, R. B., & Hamed, K. A. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0220-6 · Cited by 26
Should daptomycin–rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?
Stein, C., Makarewicz, O., Forstner, C., Weis, S., Hagel, S., Löffler, B., & Pletz, M. W. (2016) · Infection · doi:10.1007/s15010-016-0874-2 · Cited by 21
“Despite the lack of randomized trials, there is increasing clinical evidence that combination therapy of daptomycin (DAP) with rifampin (RIF) is a valuable treatment option for biofilmassociated difficult-to-treat Staphylococcus aureus infections, such as osteomyelitis, prosthetic joint infection and prosthetic valve…”
BackgroundZheng, J., Tu, H.-P., Sun, X., Xu, G., Chen, J., Deng, Q.-W., Yu, Z., & Qu, D. (2020) · Journal of Medical Microbiology · doi:10.1099/jmm.0.001122 · Cited by 21
Thacharodi, A., Hassan, S., Ahmed, T., Acharya, G., Blacknell, N.-M. G., Singh, P., Pal, S., Saraswathi, A., Kosuru, B. R., Sofi, M. A., et al. (2025) · iScience · doi:10.1016/j.isci.2025.114376 · Cited by 28
Samura, M., Takada, K., Yamamoto, R., Ito, H., Nagumo, F., Uchida, M., Kurata, T., Koshioka, S., Enoki, Y., Taguchi, K., et al. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03058-0 · Cited by 18
Grau, S., Fondevilla, E., Freixas, N., Mojal, S., Sopena, N., Bella, F., Gudiol, F., on behalf of the VINCat Group, Balet, A., Pérez, R., et al. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dku487 · Cited by 17
Analysis of the 2015 American and European guidelines for the management of infective endocarditis
Tattevin, P., & Mainardi, J. (2016) · Médecine et Maladies Infectieuses · doi:10.1016/j.medmal.2016.05.008 · Cited by 20
“good outcome associated with the use of daptomycin in the treatment of left-sided endocarditis [9, 10], it should be reminded that it has only been approved in the treatment of right-sided endocarditis where it only demonstrated a non-inferiority versus conventional treatments [11].”
BackgroundWang, G., Kamalakaran, S., Dhand, A., Huang, W., Ojaimi, C., Zhuge, J., Yee, L. L., Mayigowda, P., Surendraiah, P. K. M., Dimitrova, N., et al. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02683-14 · Cited by 18
Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa
Habib, G., Lancellotti, P., Antunes, M. J., Bongiorni, M. G., Casalta, J., Zotti, F. D., Dulgheru, R., Khoury, G. A. E., Erba, P. A., Iung, B., et al. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.11.015 · Cited by 54
Heitzmann, J., Thoma, Y., Bricca, R., Gagnieu, M., Leclerc, V., Roux, S., Conrad, A., Ferry, T., & Goutelle, S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14010114 · Cited by 16
Samura, M., Takada, K., Hirose, N., Kurata, T., Nagumo, F., Uchida, M., Inoue, J., Tanikawa, K., Enoki, Y., Taguchi, K., et al. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15671 · Cited by 18
“Several studies for bacteraemia and infective endocarditis suggested high efficacy with daptomycin at ≥8 mg/kg.(21,22) In this context, the recent guidelines on MRSA treatment recommend the use of daptomycin at ≥8 mg/kg in patients with infective endocarditis.”
BackgroundKeller, F., Schröppel, B., & Ludwig, U. (2015) · World Journal of Nephrology · doi:10.5527/wjn.v4.i3.330 · Cited by 17
Diagnosis, treatment and prevention of infective endocarditis: Turkish consensus report-2019*
Yavuz, S. Ş., Akar, A. R., Aydoğdu, S., Deniz, D. B., Demir, H., Hazırolan, T., Ozatik, M. A., Özer, N., Sargın, M., Topçuoğlu, N., et al. (2020) · Turk Kardiyoloji Dernegi Arsivi-Archives of the Turkish Society of Cardiology · doi:10.5543/tkda.2020.89689 · Cited by 25
Use of Daptomycin to Manage Severe MRSA Infections in Humans
Fiore, M., Alfieri, A., Fiore, D., Iuliano, P., Spatola, F. G., Limone, A., Pezone, I., & Leone, S. (2025) · Antibiotics · doi:10.3390/antibiotics14060617 · Cited by 18
“…eradication in 89% and overall clinical success in 86% of cases, with no treatment discontinuations due to elevated creatine phosphokinase levels; these results thereby provide evidence for the safety and effectiveness of regimens using ≥ 8 mg kg − 1 for the treatment of adults [35].”
Tirilomis, T. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00097 · Cited by 14
“However, in multicenter, retrospective studies highdose daptomycin (daily more than 8 mg/kg) were effective in complicating infections, including wound infections, with low adverse events (35, 36).”
BackgroundIm, J., Lee, D.-W., Park, O.-J., Natarajan, S., Park, J., Yun, C., & Han, S. H. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1063650 · Cited by 13
“, 2011), but these antibiotic treatments have limitations including low tissue absorption, slow bactericidal efficacy, and antibiotic resistance (Kullar et al., 2013; Moise et al., 2013; Ortwine and Bhavan, 2018).”
BackgroundDaptomycin-Containing Regimens for Treatment of Gram-Positive Endocarditis
Russo, A., Peghin, M., Givone, F., Ingani, M., Graziano, E., & Bassetti, M. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.08.011 · Cited by 14
Pharmacokinetics and pharmacodynamics of daptomycin in a clinical setting
Tsukada, H., Tsuji, Y., Yamashina, T., Tsuruta, M., Hiraki, Y., Tsuruyama, M., Ogami, C., Kawasuji, H., Sakamaki, I., & Yamamoto, Y. (2019) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2019.08.017 · Cited by 12
Tebano, G., Zaghi, I., Baldasso, F., Calgarini, C., Capozzi, R., Salvadori, C., Cricca, M., & Cristini, F. (2024) · Pathogens · doi:10.3390/pathogens13010088 · Cited by 17
Ando, M., Nishioka, H., Nakasako, S., Kuramoto, E., Ikemura, M., Kamei, H., Sono, Y., Sugioka, N., Fukushima, S., & Hashida, T. (2019) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13061 · Cited by 10
Reilly, J., Jacobs, M. A., Friedman, B. C., Cleveland, K. O., Lombardi, D. A., & Castañeda-Ruiz, B. (2020) · Drugs - Real World Outcomes · doi:10.1007/s40801-020-00191-x · Cited by 12
Synergistic Effects of Thiosemicarbazides with Clinical Drugs against S. aureus
Chudzik-Rząd, B., Malm, A., Trotsko, N., Wujec, M., Plech, T., & Paneth, A. (2020) · Molecules · doi:10.3390/molecules25102302 · Cited by 11
“Although daptomycin remains as one of the main treatment options for MRSA, sporadic resistance cases reported in patients treated with daptomycin are a growing concern [20,21].”
BackgroundYavuz, S. Ş., Akar, A., Aydoğdu, S., Berzeg-Deniz, D., Demir, H., Hazırolan, T., Özatık, M. A., Özer, N., Sarğın, M., Topçuoğlu, N., et al. (2020) · Turkish Journal of Thoracic and Cardiovascular Surgery · doi:10.5606/tgkdc.dergisi.2020.01954 · Cited by 13
Matsuo, T., Mori, N., Sakurai, A., Kanie, T., Mikami, Y., Uehara, Y., & Furukawa, K. (2021) · IDCases · doi:10.1016/j.idcr.2021.e01113 · Cited by 11
“Although there were few clinical reports related to endocarditis due to highly resistant VGS, in vitro data suggest that outcomes could be improved with higher doses for gram-positive bloodstream infections [9].”
Backgroundda Silva, G. O., Farias, B. C. S., da Silva, R. B., Teixeira, E. H., Cordeiro, R. D. A., Hissa, D. C., & Melo, V. M. M. (2021) · Medical Mycology · doi:10.1093/mmy/myab051 · Cited by 11
García-Martínez, T., Medall, M. D. B., Garcia‐Cremades, M., Ferrando‐Piqueres, R., Sanjuan, V. M., & Merino‐Sanjuán, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14102226 · Cited by 8
Minotti, C., Zuccon, I., Priante, E., Bonadies, L., Chiara, C. D., Donà, D., Baraldi, E., & Costenaro, P. (2022) · Children · doi:10.3390/children9040457 · Cited by 9
Study on daptomycin use and implementation of an antimicrobial stewardship program
Castel, C., Blanchardière, A. D. L., Michon, J., Cattoir, V., & Saint‐Lorant, G. (2016) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-016-0271-z · Cited by 7
Ross, J. K., Rankin, S., Marshik, P. L., Mercier, R.-C., Brett, M., & Walraven, C. J. (2015) · Antibiotics · doi:10.3390/antibiotics4030309 · Cited by 8
Olney, K. B., Howard, J., & Burgess, D. S. (2024) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2425 · Cited by 7
O'Connor, C., Casserly, L. F., Qazi, J., Power, L., Finnegan, C., O’Connell, N. H., & Dunne, C. P. (2015) · JMM Case Reports · doi:10.1099/jmmcr.0.000089 · Cited by 7
“The use of daptomycin at higher doses of i 8 mg kg 2 1 day 2 1 (Kullar et al. , 2011, 2013) and 14 mg kg 2 1 day 2 1 (Moise et al. , 2009) for the treatment of infective endocarditis have been demonstrated with no adverse patient outcomes.”
Daptomycin for the treatment of major gram-positive infections after cardiac surgery
Kornberger, A., Luchting, B., Kur, F., Weis, M., Weis, F. C., Stock, U. A., & Beiras-Fernández, A. (2016) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-016-0519-7 · Cited by 6
Sandoval, N., Grau, S., Sorlí, L., Montero, M., Esteve, E., & Horcajada, J. P. (2015) · Future Microbiology · doi:10.2217/fmb.15.41 · Cited by 8
García-de-la-Mària, C., Gasch, O., Cañas, M. A., García‐González, J., Marco, F., Meneses, M. H., Quintana, E., Ambrosioni, J., Falces, C., Tolosana, J. M., et al. (2025) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaf245 · Cited by 6
Fiore, M., & Andreana, L. (2015) · Infectious Disease Reports · doi:10.4081/idr.2015.6286 · Cited by 5
False Prolongation of Prothrombin Time in the Presence of a High Blood Concentration of Daptomycin
Yamada, T., Kato, R., Oda, K., Tanaka, H., Suzuki, K., Ijiri, Y., Ikemoto, T., Nishihara, M., Hayashi, T., Tanaka, K., et al. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12597 · Cited by 5
Zhao, M., Chen, F., Yang, W., Yan, T., & Chen, Q. (2025) · Scientific Reports · doi:10.1038/s41598-025-06800-5 · Cited by 4
Tsai, C.-Y., Lee, C., & Chen, I. (2018) · Infection and Drug Resistance · doi:10.2147/idr.s184411 · Cited by 4
“Furthermore, Kullar et al revealed that high-dose daptomycin, defined as ≥8 mg/ kg/day, was an effective and safe antimicrobial in patients with infective endocarditis.(9) As a result, Infectious Diseases Society of America (IDSA) guidelines for the treatment of MRSA BSI recommend consideration of high-dose daptomycin…”
Pharmacodynamics of Daptomycin
Wenzler, E., Liao, S., & Rodvold, K. A. (2016) · Methods in pharmacology and toxicology · doi:10.1007/978-1-4939-3323-5_13 · Cited by 4
Kern, W. V. (2014) · Springer eBooks · doi:10.1007/978-3-662-44000-1_14 · Cited by 4
Gregori, S. D., SILVESTRI, A. D., Capone, M., Monzillo, V., Giordani, P., Bruno, R., & Seminari, E. M. (2025) · Therapeutic Advances in Infectious Disease · doi:10.1177/20499361241296232 · Cited by 6
Daptomycin and Ampicillin Combination for Treatment of Enterococcus faecalis Endocarditis
Sierra‐Hoffman, M., Iznaola, O., Lamp, K. C., Mohr, J., & Winn, R. E. (2015) · Infectious Diseases in Clinical Practice · doi:10.1097/ipc.0000000000000282 · Cited by 3
Lash, D. B., Joson, J., & Heidari, A. (2015) · Case Reports in Infectious Diseases · doi:10.1155/2015/175810 · Cited by 2
“We present a case that illustrates some of these issues clinicians are facing.”
BackgroundSaany, M. A., & Jahangiri, A. (2026) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2026.103264 · Cited by 2
A case of daptomycin-induced acute eosinophilic pneumonia
Nakashima, I., Sekido, Y., Gushima, Y., & Maehara, J. (2016) · Journal of the Japanese Society of Intensive Care Medicine · doi:10.3918/jsicm.23.55 · Cited by 1
Daptomycin zur Behandlung grampositiver Infektionen nach herzchirurgischen Eingriffen
Luchting, B., Weis, F. C., Heyn, J., & Beiras-Fernández, A. (2012) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-012-0163-5
“A role for high-dose daptomycin was also suggested for the treatment of infective endocarditis (IE) including left-sided and double-sided IE [43, 46–48].”
BackgroundAdvances in the Diagnosis and Treatment of Infective Endocarditis
Turner, R. B., & Schwartz, J. (2017) · Advances in medical diagnosis, treatment, and care (AMDTC) book series · doi:10.4018/978-1-5225-2092-4.ch010
Antibiothérapie des endocardites infectieuses : lecture critique des recommandations 2015
Tattevin, P. (2017) · Journal des Anti-infectieux · doi:10.1016/j.antinf.2017.01.001
OBSOLETE: Infective Endocarditis in the 21st Century
Mehta, J. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99720-4
Holubar, M. K., Meng, L., & Deresinski, S. C. (2016)
The use of daptomycin for the treatment of infectious endocarditis: results of a multicenter study
Shevchenko, Y. L., Tyurin, V. P., Popov, L. V., Григорьевич, Г. В., Павликова, Е. П., Леонардович, Б. Н., Fedorova, T. A., Rusanov, N. I., & Tazina, S. Y. (2017) · Clinical Medicine (Russian Journal) · doi:10.18821/0023-2149-2017-95-4-328-332
Facts and hypotheses of antibacterial therapy in cardiology
Zhuravlyova, L., Кулікова, М. В., & Кузнецов, И. В. (2017) · Medicine of Ukraine · doi:10.37987/1997-9894.2017.7(213).222350
Infective Endocarditis in 21st Century
Kandasamy, V. V., Pant, S., & Mehta, J. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99720-5
Infective endocarditis - new therapeutic strategies
Andra Ioana, N. U. T. A., & Diaconu, C. C. (2022) · Annals of the Academy of Romanian Scientists Series of Medicine · doi:10.56082/annalsarscimed.2022.2.7
Almangour, T. A., Almosabhi, L., Almojel, R., Althubaity, R., Almuhisen, S., Almohaizeie, A., Alowais, S. A., Saleh, K. B., Damfu, N., Alotaibi, S., et al. (2026) · Infection and Drug Resistance · doi:10.2147/idr.s572989
Metadata
- Authors
- Kullar, R., Casapao, A. M., Davis, S. L., Levine, D. P., Zhao, J. J., Crank, C. W., Segreti, J., Sakoulas, G., Cosgrove, S. E., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Detroit Medical Center (US)
- Rush University Medical Center (US)
- Sharp Memorial Hospital (US)
- Johns Hopkins University (US)
- Corresponding author
- Rybak, M. J.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-08-08
- Volume
- 68
- Issue
- 12
- Pages
- 2921-2926
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- PMC
- PMC3820108
- OpenAlex
- W2096479937
- Cited by
- 99
- References
- 36
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 2 · 2023: 4 · 2022: 5 · 2021: 4 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 8 · 2016: 17 · 2015: 22 · 2014: 8
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Antimicrobial Chemotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- U.S. Public Health Service (R21A1092055-01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Infective Endocarditis Diagnosis and Management
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
- Keywords
- daptomycin, high-dose daptomycin, infective endocarditis, staphylococcal endocarditis, enterococcal endocarditis, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, right-sided endocarditis, left-sided endocarditis, salvage therapy, combination therapy, treatment efficacy, drug safety, creatine kinase elevation
- MeSH terms
- Adult, Anti-Bacterial Agents, Blood, Endocarditis, Female, Humans, Male, Middle Aged, Retrospective Studies, Staphylococcus aureus, Treatment Outcome, Gram-Positive Bacterial Infections, Enterococcus, Daptomycin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.